Search results
Results from the WOW.Com Content Network
Bristol Myers Squibb and Karuna announced their merger agreement on Friday. The transaction, which amounts to $330 per share in cash, offers a premium of 53% over Karuna's stock on Thursday.
Xanomeline was licensed to Karuna Therapeutics in 2012 and KarXT was subsequently created as a dual drug formulation by adding trospium. Trospium is a non-brain-penetrant and non-selective muscarinic receptor blocker that may ameliorate the peripheral side effects of xanomeline.
[19] [20] As of 2020, he was on the board of directors or is a trustee of several organizations, including serving as chairman of the Board of the Foundation for the NIH (FNIH) [21] and as a Director of Alnylam Pharmaceuticals, [22] Sage Therapeutics, [23] Voyager Therapeutics [24] and Karuna Pharmaceuticals. [25]
If Karuna is successful, its drug would offer relief to a large patient population. According to the World Health Organization, schizophrenia affects approximately 24 million people, or one in 300 ...
The acquisition included Karuna's lead asset, KarXT, an investigational muscarinic antipsychotic combination of Xanomeline and Trospium. [86] In November 2023, the FDA accepted Karuna Therapeutics' NDA for KarXT, for the treatment of schizophrenia in adults. [87] The acquisition of Karuna Therapeutics was completed in March 2024. [88]
By Michael Erman and Manas Mishra (Reuters) -Bristol Myers Squibb on Friday agreed to buy Karuna Therapeutics for $14 billion, gaining a promising new type of antipsychotic medicine to help power ...
In October, Bristol announced an up to $5.8 billion deal to buy cancer drugmaker Mirati Therapeutics, while Eli Lilly had said it will buy radiopharmaceutical firm Point Biopharma for $1.4 billion.
Previous logo. Companies which PureTech Health founded include Karuna Pharmaceuticals, [4] Gelesis, which has received FDA approval as a treatment for weight management, [5] Akili Interactive Labs, which is developing a digital therapeutic platform for cognitive disorders, [6] Vedanta Biosciences, which is developing drugs to treat autoimmune and inflammatory diseases, [7] and Follica which is ...